Healthy newborn infants rarely Buffer from thrombosis, despite their low plasma antithrombin III (ATIII) levels. In adults, ATIII is the main inhibitor of thrombin; α 2-macroglobulin (α 2 M) and ...
– Company Remains on Track to File Investigational New Drug Application in Mid-2013 and to Initiate Phase I in Late 2013 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ...
A research group consisting of Professor Masahiro Nishibori (Specially Appointed Professor）, Department of Translational Research and Drug Development, Faculty of Medicine, Dentistry and ...
INNOVANCE Antithrombin assay is a cutting-edge, ready-to-use chromogenic reagent for the automated determination of antithrombin (AT) activity. It is highly accurate even at low activity levels and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 study with ALN-AT3, a ...
The assay now can measure antithrombin (AT) activity levels for people treated with Qfitlia Qfitila will support people living with hemophilia A or B, with or without inhibitors, by helping to ...
Dose and frequency should be adjusted based on antithrombin activity, using the Innovance Antithrombin companion diagnostic test. The Food and Drug Administration (FDA) has approved Qfitlia (fitusiran ...
– Company Remains on Track to File Investigational New Drug Application in Mid-2013 and to Initiate Phase I in Late 2013 – "Hemophilia and other rare bleeding disorders are characterized by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results